[go: up one dir, main page]

MX2018013523A - Anticuerpos monoclonales de adn dirigidos a il-6 y cd126. - Google Patents

Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.

Info

Publication number
MX2018013523A
MX2018013523A MX2018013523A MX2018013523A MX2018013523A MX 2018013523 A MX2018013523 A MX 2018013523A MX 2018013523 A MX2018013523 A MX 2018013523A MX 2018013523 A MX2018013523 A MX 2018013523A MX 2018013523 A MX2018013523 A MX 2018013523A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
antibodies targeting
dna monoclonal
composition
dna
Prior art date
Application number
MX2018013523A
Other languages
English (en)
Inventor
Weiner David
Elliott Sarah
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018013523A publication Critical patent/MX2018013523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe en la presente una composicion que incluye una secuencia de acido nucleico recombinante que codifica un anticuerpo sintetico anti-IL-6 y/o anti-CD126; la descripción tambien proporciona un metodo para prevenir y/o tratar una enfermedad en un sujeto utilizando dicha composicion y metodo de generacion.
MX2018013523A 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos a il-6 y cd126. MX2018013523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Publications (1)

Publication Number Publication Date
MX2018013523A true MX2018013523A (es) 2019-06-10

Family

ID=60203626

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013523A MX2018013523A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
MX2025009846A MX2025009846A (es) 2016-05-05 2018-11-05 Composiciones que comprenden moleculas de acido nucleico que codifican anticuerpos sinteticos anti-il-6 y anti-cd126

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025009846A MX2025009846A (es) 2016-05-05 2018-11-05 Composiciones que comprenden moleculas de acido nucleico que codifican anticuerpos sinteticos anti-il-6 y anti-cd126

Country Status (12)

Country Link
US (1) US20190192692A1 (es)
EP (1) EP3452106A4 (es)
JP (3) JP7311113B2 (es)
KR (3) KR20230058733A (es)
CN (1) CN109789224A (es)
AU (2) AU2017261292B2 (es)
BR (1) BR112018072697A2 (es)
CA (1) CA3023089A1 (es)
EA (1) EA201892524A1 (es)
MX (2) MX2018013523A (es)
SG (2) SG11201809786TA (es)
WO (1) WO2017192933A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190284261A1 (en) * 2016-11-07 2019-09-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against lyme disease
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1562968E (pt) * 2001-11-14 2013-10-23 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
ES2525325T3 (es) * 2005-12-09 2014-12-22 Ucb Pharma S.A. Moléculas de anticuerpo que tienen especificidad por la IL-6 humana
AU2007282023B2 (en) * 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
ES2564635T3 (es) * 2008-05-13 2016-03-28 Novimmune Sa Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
AU2011332810A1 (en) * 2010-11-23 2013-06-13 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
HK1213481A1 (zh) * 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015054293A1 (en) * 2013-10-07 2015-04-16 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of psoriatic arthritis

Also Published As

Publication number Publication date
EP3452106A1 (en) 2019-03-13
JP2019518074A (ja) 2019-06-27
BR112018072697A2 (pt) 2019-02-19
SG10202011023YA (en) 2020-12-30
AU2017261292B2 (en) 2024-06-06
AU2024203109A1 (en) 2024-05-30
MX2025009846A (es) 2025-09-02
SG11201809786TA (en) 2018-12-28
EP3452106A4 (en) 2020-01-08
JP2023086734A (ja) 2023-06-22
CN109789224A (zh) 2019-05-21
AU2017261292A1 (en) 2018-12-20
KR20230058733A (ko) 2023-05-03
US20190192692A1 (en) 2019-06-27
WO2017192933A1 (en) 2017-11-09
KR20190031439A (ko) 2019-03-26
JP2025147175A (ja) 2025-10-06
CA3023089A1 (en) 2017-11-09
JP7311113B2 (ja) 2023-07-19
KR20250011241A (ko) 2025-01-21
EA201892524A1 (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
MX2024000125A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
MX393951B (es) Anticuerpos antisortilina y métodos para su uso.
MX384138B (es) Anticuerpos anti-c5 y métodos para su uso.
EA201890028A1 (ru) Антитело, связывающее cd3 человека
AR103488A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EA201891410A1 (ru) Антитела к с5 и способы их применения
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
MX2024000118A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
AR118763A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
AR100367A1 (es) Anticuerpos biespecíficos químicamente bloqueados
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
EA201892124A1 (ru) Днк-конструкции антител и способы их применения
EA201892523A1 (ru) Днк-моноклональные антитела, нацеленные на вирус гриппа